ClinicalTrials.gg
CompletedNCT02125253Updated Nov 2, 2015

Study to Compare the Therapeutic Equivalence of Mometasone Furoate Nasal Spray, 50 mcg With Nasonex Nasal Spray in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis

A Phase 3 interventional study of Mometasone Furoate Nasal Spray, 50 mcg and Nasonex Nasal Spray, 50 mcg in Seasonal Allergic Rhinitis, sponsored by Amneal Pharmaceuticals, LLC. Completed at 10 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2015-11-02.

Sponsored by Amneal Pharmaceuticals, LLC · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
811
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 107 studies in Rhinitis, Allergic, Seasonal with a site in United States — 1 open to participants now, 1 under way, none of them phase 3. Rhinitis, Allergic, Seasonal · United States.

Enrollment
17th of 101
811 · median 446
Started
2014
with 5 others
Phase 3
47 of 107
none open now
Registered
90th of 107
by date

Among the 107 studies in Rhinitis, Allergic, Seasonal with a site in United States, this one is the 17th largest by enrollment of the 101 interventional ones that give a count, is one of 6 that started in 2014, is one of 47 in phase 3, and was the 90th registered.

Rhinitis, Allergic, Seasonal

404 studies on the registry are indexed under Rhinitis, Allergic, Seasonal; 24 are open to participants now.

Browse Rhinitis, Allergic, Seasonal studies →

Open to participants now

1 of the 107 studies in Rhinitis, Allergic, Seasonal with a site in United States is open now. Recruiting first, the newest first:

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 17 Rhinitis, Allergic, Seasonal studies recruiting now, 2 (12%) set no upper age limit and 15 (88%) stop at 75 or younger; 1 takes children under 18; 5 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 107 studies in Rhinitis, Allergic, Seasonal with a site in United States, or all of them as a file.
02

Study summary

To evaluate the therapeutic equivalence of the lest formulation of Mometasone Furoate Nasal Spray, 50 mcg to the marketed formulation NASONEX® (mometasone furoate monohydrate) Nasal Spray, 50 mcg/actuation in patients with seasonal allergic rhinitis

03

Conditions studied

  • Seasonal Allergic Rhinitis
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • If female and of , have a negative urine pregnancy test and is prepared to abstain from sexual intercourse or use a reliable method of during the study
  • Documented positive allergic skin test, performed within the previous 12 months, to one or more of the allergens in season at the time the study is being conducted.
  • A minimum of two consecutive years of previous history of seasonal allergic rhinitis to the pollen/allergen in season at the time the study is being conducted.
  • A score of at least 6 on the reflective Total Nasal Symptom Score (rTNSS) and a minimum score of at least 2 for "nasal congestion" and a minimum score of at least 2 for one of the remaining 3 symptoms representing the 12hours prior to the screening visit.
  • An average composite score of at least 6 on the rTNSS and a minimum score of at least 2 for "nasal congestion" and a minimum score of at least 2 for one of the remaining 3 symptoms representing the last 3 days of the 7-day placebo lead-in period before the randomization visit and the morning of the first day.

of the randomization visit.

Exclusion criteria

Exclusion Criteria:

  • Females who are pregnant, lactating or likely to become pregnant during the study.
  • Negative or lack of documented skin allergen test (performed within the previous 12 months) to at least one of the allergens in season at the time the study is being conducted.
  • Patients who suffer from chronic signs and symptoms of Perennial Allergic Rhinitis, unless the investigator assesses that the patient's current signs and symptoms are a clear exacerbation of Seasonal Allergic Rhinitis (SAR) rather than chronic PAR.
  • Patients who suffer only from perennial allergic rhinitis or seasonal allergic rhinitis to a different allergen than that in season at the time the study is conducted.
  • Previous history of less than 2 years of seasonal allergic rhinitis to the pollen/allergen in season at the time the study is being conducted.
  • Any patient who meets the minimum rTNSS requirements at the start of the placebo lead-in period but no longer meets the requirements prior to the randomized active treatment period of the study cannot continue in the active treatment period.
  • History of asthma over the previous two years that required chronic therapy. Occasional acute or mild exercise induced asthma will be allowable on the condition that the treatment of the attacks is restricted to beta-agonists only.
  • Patients with nasal conditions, including infectious rhinitis, rhinitis medicamentosa or atrophic rhinitis.
  • nasal deformity or any recent nasal surgery or trauma that has not completely healed.
  • Sinus infection within the previous 30 days or history of reoccurring sinus infections.
  • Patient has started immunotherapy or changed their dose of immunotherapy within 30 days of the first placebo lead-in dose or is likely to have to start immunotherapy, or change their current dose during the study.
  • Treatment for oral Candidiasis within 30 days of starting the study or a current oral Candidiasis infection.
  • Upper respiratory tract infection within the previous 30 days.
  • Patients with a history of tuberculosis.
  • Patients with the presence of glaucoma, cataracts, ocular herpes simplex, conjunctivitis or other eye infection not related to the diagnosis of SAR within 14 days of enrollment.
  • The patient has had recent exposure (30 days) or was at risk of being exposed to chicken pox or measles.
  • Patients with any untreated fungal, bacterial, systemic viral infections within the previous 30 days.
  • Use of any ophthalmic within 14 days or nasal, inhaled or systemic steroids within 30 days of the study start.
  • Use of the reference product, Nasonex® within 3 months of the study start.
  • Use of intranasal or systemic second-generation anti-histamines within10 days of enrollment.
  • Use of intranasal cromolyn within 14 days of enrollment.
  • Use of intranasal or systemic first-generation anti-histamines, leukotriene receptor antagonists or other nasal decongestants within 3 days of enrollment.
  • Use of any tricyclic anti-depressant within 30 days of enrollment
  • Patients with attention-deficit disorder being treated with methylphenidate containing products that have not been on a stable dosing regimen for at least the 30 previous days and who cannot remain on the same dosing regimen throughout the study.
  • Desensitization therapy to the seasonal allergen that is causing the patients allergic rhinitis within the previous 6 months.
  • Previous SAR and/or PAR that has proven unresponsive to steroid therapy.
  • Any known to mometasone, other steroids or any of the components of the study nasal spray.
  • Significant history or current evidence of chronic infectious disease, system disorder, organ disorder or other medical condition that in the Investigator's opinion would place the study patient at undue risk by participating or could jeopardize the integrity of the study evaluations.
  • Receipt of any drug as part of a research study within 30 days prior to the first placebo lead-in dose.
  • Planned travel outside of the local area for more than 2 consecutive days or 3 days in total, during the patient's participation in the study.
  • Previous participation in this study.
  • The patient currently smokes cigarettes, cigars, and/or pipes and is a heavy smoker
  • The patient shares a household with another patient currently enrolled in this study
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
811 participants (actual)

Study arms

  • Experimental
    Mometasone Furoate Nasal Spray, 50 mcg

    Mometasone Furoate Nasal Spray, 50 mcg. 4 actuations per day for 14 days.

    Drug: Mometasone Furoate Nasal Spray, 50 mcg

  • Active comparator
    Nasonex Nasal Spray, 50 mcg

    Nasonex (mometasone furoate monohydrate) Nasal Spray, 50 mcg. 4 actuations per day for 14 days.

    Drug: Nasonex Nasal Spray, 50 mcg

  • Placebo comparator
    Placebo Nasal Spray

    Placebo of Mometasone Furoate Nasal Spray. 4 actuations per day for 14 days.

    Drug: Placebo Nasal Spray

Interventions

  • DrugMometasone Furoate Nasal Spray, 50 mcg

    a metered-dose, manual pump spray unit containing an aqueous suspension of mometasone furoate

  • DrugNasonex Nasal Spray, 50 mcg

    a metered-dose, manual pump spray unit containing an aqueous suspension of mometasone furoate monohydrate

  • DrugPlacebo Nasal Spray

    a metered-dose, manual pump spray unit containing an aqueous suspension

06

What researchers measure

Primary outcomes

  1. Change from Baseline rTNSS

    Change from baseline in average AM/PM reflective Total Nasal Symptom Score (rTNSS) over Days 1 to 14

    Time frame: Days 1 - 14

  2. Total Nasal Symptom Score (TNSS)

    The sum of patient-rated severity scores for four allergy symptoms : runny nose, nasal congestion, itchy nose, and sneezing based on a 4-point scale.

    Time frame: Days 1 - 14

Secondary outcomes

  1. Change in Baseline iTNSS

    Change from baseline in average instantaneous Total Nasal Symptom Score (iTNSS) over Days 1 to 14.

    Time frame: Days 1 - 14

07

Study locations

10 sites
  • Isis Clinical Research
    Austin, Texas 78731, United States
  • Austin Clinical Research
    Austin, Texas 78750, United States
  • Sirius Clinical Research
    Austin, Texas 78759, United States
  • Kerrville Research Associates
    Kerrville, Texas 78028, United States
  • Central Texas Health Research
    New Braunfels, Texas 78130, United States
  • Allergy & Asthma Research Center
    San Antonio, Texas 78229, United States
  • Biogenics Research Institute
    San Antonio, Texas 78229, United States
  • Diagnostics Research Group
    San Antonio, Texas 78229, United States
  • Sylvania Research
    San Antonio, Texas 78229, United States
  • Allergy & Asthma Care of Waco
    Waco, Texas 76708, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2014, a primary completion of Mar 2014 and a completion of Jun 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2014
First posted
Apr 29, 2014
Start
Jan 2014
Primary completionActual
Mar 2014
CompletionActual
Jun 2014
Results delay requested
Jul 9, 2014
Last update
Nov 2, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 2, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02125253
Collaborators
Novum Pharmaceutical Research Services
Responsible party
Sponsor
First posted
Apr 29, 2014
Start date
Jan 2014
Primary completion
Mar 2014
Completion
Jun 2014
Last update
Nov 2, 2015

Study contacts

Keith Gallicano, PhD
study chair · Novum Pharmaceutical Reserach Services

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion